Alliqua Inc. (NASDAQ:ALQA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday.

According to Zacks, “Alliqua, Inc. is a biomedical company. The company focused on the development, manufacturing and distribution of proprietary transdermal wound care and drug delivery technologies. Its technology platform produces hydrogels, a 3-dimensional cross-linked network of water soluble polymers. The company’s product includes SilverSeal(R) a hydrogel wound dressing with silver coated fibers and Hydress(R) an over-the-counter hydrogel wound dressing. It serves the healthcare industry including wound healing, medical diagnostics and cosmeceuticals. Alliqua, Inc. is headquartered in Langhorne, Pennsylvania. “

Separately, HC Wainwright reissued a “buy” rating on shares of Alliqua in a report on Tuesday, November 8th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $2.42.

Analyst Recommendations for Alliqua (NASDAQ:ALQA)

Shares of Alliqua (NASDAQ:ALQA) opened at 0.60 on Thursday. The stock’s market cap is $17.80 million. The firm has a 50-day moving average of $0.75 and a 200 day moving average of $0.99. Alliqua has a 52 week low of $0.57 and a 52 week high of $2.85.

Several hedge funds and other institutional investors have recently modified their holdings of ALQA. Suffolk Capital Management LLC boosted its position in shares of Alliqua by 4.8% in the third quarter. Suffolk Capital Management LLC now owns 1,264,101 shares of the company’s stock valued at $1,011,000 after buying an additional 57,974 shares during the period. US Bancorp DE boosted its position in shares of Alliqua by 29.8% in the second quarter. US Bancorp DE now owns 181,732 shares of the company’s stock valued at $204,000 after buying an additional 41,732 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Alliqua by 1.1% in the second quarter. Vanguard Group Inc. now owns 524,296 shares of the company’s stock valued at $587,000 after buying an additional 5,780 shares during the period. 30.34% of the stock is owned by hedge funds and other institutional investors.

Alliqua Company Profile

Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.

5 Day Chart for NASDAQ:ALQA

Receive News & Stock Ratings for Alliqua Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Inc. and related stocks with our FREE daily email newsletter.